• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.

作者信息

Molica Stefano, Giannarelli Diana, Visentin Andrea, Reda Gianluigi, Sportoletti Paolo, Frustaci Anna Maria, Chiarenza Annalisa, Ciolli Stefania, Vitale Candida, Laurenti Luca, De Paoli Lorenzo, Murru Roberta, Gentile Massimo, Moia Riccardo, Rigolin Gian Matteo, Levato Luciano, Giordano Annamaria, Del Poeta Giovanni, Stelitano Caterina, Deodato Marina, Ielo Claudia, Noto Alessandro, Guarente Valerio, Coscia Marta, Tedeschi Alessandra, Gaidano Gianluca, Cuneo Antonio, Foa' Robin, Trentin Livio, Mauro Francesca Romana

机构信息

Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.

Biostatistic Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

出版信息

Am J Hematol. 2022 May;97(5):E176-E180. doi: 10.1002/ajh.26502. Epub 2022 Feb 25.

DOI:
10.1002/ajh.26502
PMID:35170793
Abstract
摘要

相似文献

1
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.依鲁替尼治疗慢性淋巴细胞白血病患者的预后预测：当前预后模型的验证及简化三因素模型的建立
Am J Hematol. 2022 May;97(5):E176-E180. doi: 10.1002/ajh.26502. Epub 2022 Feb 25.
2
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.接受依鲁替尼治疗的慢性淋巴细胞白血病患者的预后模型：比较性能分析结果
Eur J Haematol. 2021 Mar;106(3):425-427. doi: 10.1111/ejh.13548. Epub 2020 Nov 29.
3
Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的早期治疗中使用依鲁替尼可产生更好的治疗效果。
Leuk Lymphoma. 2021 Dec;62(13):3278-3282. doi: 10.1080/10428194.2021.1957871. Epub 2021 Aug 13.
4
Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.伊布替尼作为慢性淋巴细胞白血病的初始治疗：一项系统评价和荟萃分析。
Eur J Haematol. 2020 May;104(5):512-515. doi: 10.1111/ejh.13387. Epub 2020 Feb 22.
5
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.接受依鲁替尼治疗的真实世界复发/难治性慢性淋巴细胞白血病患者的生存风险评分。一项校园慢性淋巴细胞白血病研究。
Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.
6
Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.依鲁替尼治疗慢性淋巴细胞白血病患者过程中出现的乙型肝炎病毒再激活
Turk J Haematol. 2020 Aug 28;37(3):208-209. doi: 10.4274/tjh.galenos.2020.2019.0180. Epub 2020 Apr 6.
7
Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.在慢性淋巴细胞白血病中，坚持使用依鲁替尼仍然是一项未满足的临床需求。
Leuk Lymphoma. 2022 Aug;63(8):1771-1773. doi: 10.1080/10428194.2022.2087072. Epub 2022 Jun 15.
8
Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.依鲁替尼诱发慢性淋巴细胞白血病患者的心包填塞
Turk J Haematol. 2021 Feb 25;38(1):83-85. doi: 10.4274/tjh.galenos.2020.2020.0446. Epub 2020 Nov 9.
9
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.伊布替尼治疗的慢性淋巴细胞白血病（CLL）患者的心房颤动：风险预测、管理和临床结局。
Ann Hematol. 2021 Jan;100(1):143-155. doi: 10.1007/s00277-020-04094-3. Epub 2020 Jun 1.
10
Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者中与依鲁替尼相关的非感染性不良事件的自然病程
Leuk Lymphoma. 2021 Mar;62(3):716-721. doi: 10.1080/10428194.2020.1838508. Epub 2020 Nov 19.

引用本文的文献

1
Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs.慢性淋巴细胞白血病：新药时代的预后因素
Cancers (Basel). 2024 Jul 31;16(15):2732. doi: 10.3390/cancers16152732.
2
Prognostic impact of chronic lymphocytic leukemia comorbidity index in a young population: a real-world evidence study of a national gulf region cohort.年轻人群慢性淋巴细胞白血病合并症指数的预后影响：海湾地区国家队列的真实世界证据研究。
BMC Cancer. 2024 May 13;24(1):584. doi: 10.1186/s12885-024-12343-1.
3
Evaluation of the CLL-IPI and IPS-E Prognostic Indices in a Young Middle Eastern Population with Chronic Lymphocytic Leukemia: A Retrospective Analysis at the Kuwait Cancer Control Center.
评估年轻中东人群慢性淋巴细胞白血病的 CLL-IPI 和 IPS-E 预后指数：科威特癌症控制中心的回顾性分析。
Med Princ Pract. 2023;32(3):192-199. doi: 10.1159/000533284. Epub 2023 Jul 28.
4
Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.慢性淋巴细胞白血病治疗的进展：泽布替尼作为首选治疗方案的崛起。
Cancers (Basel). 2023 Jul 23;15(14):3737. doi: 10.3390/cancers15143737.
5
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection.二次治疗时间可用于预测慢性淋巴细胞白血病的总生存期：确定风险因素有助于指导治疗选择。
Leuk Lymphoma. 2023 Feb;64(2):300-311. doi: 10.1080/10428194.2022.2148218. Epub 2022 Dec 12.
6
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study.奥比妥珠单抗联合苯丁酸氮芥与伊布替尼治疗既往未治疗的无TP53缺失的慢性淋巴细胞白血病患者：一项真实世界的慢性淋巴细胞白血病临床研究。
Front Oncol. 2022 Nov 21;12:1033413. doi: 10.3389/fonc.2022.1033413. eCollection 2022.